Compare Amphastar Pharmaceuticals Inc (AMPH) vs Capital One Financial Corp. (COF) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Capital One (COF) trades at $201.52, up 0.71% with a bearish technical signal but strong analyst support. The company reported mixed Q1 2026 earnings with a slight miss, while revenue surged to $53.43B in 2025. Key risks include subprime auto loan delinquencies and consumer credit stress, though the Discover integration offers long-term scale benefits. Technical indicators show neutral RSI readings with support at $195 and resistance at $203.

Wall Street maintains a bullish outlook with 62.5% buy ratings and a $256.25 consensus price target, representing 27% upside potential. However, declining profit margins and rising default risks in consumer lending create headwinds. The stock presents a compelling entry point for investors betting on operational improvements from recent acquisitions, though credit quality trends warrant close monitoring.